ALK and neoplasm: Furthermore, excluding patients whose tumors harbored EGFR or ALK mutations (who are ineligible for pembrolizumab within the approved indication), 1 L IO monotherapy was received in the final full quarter by 30.8% (41/133) of all patients, which is consistent with the incidence of PD-L1 tumor proportion score ≥ 50% reported in the KEYNOTE-024 trial (30.2% of all screened patients with PD-L1 status) in this population [7].